NASDAQ · RANI

Rani Therapeutics Holdings, Inc.

Healthcare · Biotechnology

$0.78▼ 1.46% ($0.01)at close

After hours$0.81▲ 4.13%7:41 PM ET

52-week

$0.45$3.87

Market cap

$50.81M

P/E

-2.89

EPS (TTM)

-$0.16

Next earnings

Nov 5, 2026

What the market price implies · Reverse DCF

To support a price of $0.78, this model requires revenue to grow by 45.08%/yr over the next 10 years, compounded annually.

Historical revenue grew by -11.95%/yr over the past 4 years. The required annual growth rate is 57.03 percentage points higher.

Selected forecast · Base scenario

13.27%/yr · actual 10-year annualized revenue growth

Year 1 growth: 20.83%

Market-implied · Base operating assumptions + edited margins

45.08%/yr · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

Valuation

Recommended · Revenue & margin DCF

Price used

$0.78

Estimated value / share

$0.24

Base scenario

This estimate is 69.28% below the price used.

USD · TTM ending 2026-06-30

Only 3 of the five annual revenue periods are available; growth uses the observed fiscal-year spans. Annual revenue history contains a gap; multi-year changes are annualized over their actual fiscal-year span.

Year 1 growth 20.83% · Ending margin 0% · Discount rate 8.97%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 22, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 23, 2026, 1:13 AM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Fundamentals are supporting the moveModerate confidence

1Y Price: 56.71%Revenue (TTM): 306.42%FCF (TTM): 34.92%

What changed

The stock rose 56.71% over the last year. Revenue grew 306.42% over the trailing twelve months. Operating margin moved from -4,106.25% to -675.8%. Free cash flow grew 34.92% over the trailing twelve months.

What the market seems to be pricing

The stock move broadly lines up with stronger business momentum. The operating data is doing enough work that the move does not need an overvaluation story to explain it.

What would invalidate this read

Operating margin is at -675.8%. Revenue grew 306.42% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.

Performance

Return analysis

Company profile

Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration.

CEOTalat Imran

SectorHealthcare

IndustryBiotechnology

Employees70

IPO dateJul 30, 2021

https://www.ranitherapeutics.com

Market multiples

Forward P/E—

EV/EBITDA-2.02

Enterprise value$74.99M

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth—

Gross margin (FY2025)44.89%▼55.1ppvs FY2024

Operating margin (FY2025)-2,345.99%▲2840.2ppvs FY2024

ROEN/A

Analyst consensus

RatingBuy

Target price$15.67▲1914.40%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 5, 2026

Q4 FY26 · EPS est -$0.05 · Revenue est $1.28M

View

NASDAQ · RANI

Rani Therapeutics Holdings, Inc.

Healthcare · Biotechnology

$0.78▼ 1.46% ($0.01)at close

After hours$0.81▲ 4.13%7:41 PM ET

52-week

$0.45$3.87

Market cap

$50.81M

P/E

-2.89

EPS (TTM)

-$0.16

Next earnings

Nov 5, 2026

What the market price implies · Reverse DCF

To support a price of $0.78, this model requires revenue to grow by 45.08%/yr over the next 10 years, compounded annually.

Historical revenue grew by -11.95%/yr over the past 4 years. The required annual growth rate is 57.03 percentage points higher.

Selected forecast · Base scenario

13.27%/yr · actual 10-year annualized revenue growth

Year 1 growth: 20.83%

Market-implied · Base operating assumptions + edited margins

45.08%/yr · flat 10-year annualized revenue growth

Valuation

Recommended · Revenue & margin DCF

Price used

$0.78

Estimated value / share

$0.24

Base scenario

This estimate is 69.28% below the price used.

USD · TTM ending 2026-06-30

Year 1 growth 20.83% · Ending margin 0% · Discount rate 8.97%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 22, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 23, 2026, 1:13 AM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Fundamentals are supporting the moveModerate confidence

1Y Price: 56.71%Revenue (TTM): 306.42%FCF (TTM): 34.92%

What changed

What the market seems to be pricing

The stock move broadly lines up with stronger business momentum. The operating data is doing enough work that the move does not need an overvaluation story to explain it.

What would invalidate this read

Performance

Return analysis

Company profile

Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration.

CEOTalat Imran

SectorHealthcare

IndustryBiotechnology

Employees70

IPO dateJul 30, 2021

https://www.ranitherapeutics.com

Market multiples

Forward P/E—

EV/EBITDA-2.02

Enterprise value$74.99M

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth—

Gross margin (FY2025)44.89%▼55.1ppvs FY2024

Operating margin (FY2025)-2,345.99%▲2840.2ppvs FY2024

ROEN/A

Analyst consensus

RatingBuy

Target price$15.67▲1914.40%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 5, 2026

Q4 FY26 · EPS est -$0.05 · Revenue est $1.28M

View